NCT00932282View on ClinicalTrials.gov

Peanut Oral Immunotherapy and Anti-Immunoglobulin E (IgE) for Peanut Allergy

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

13

Participants

Timeline

Start Date

July 31, 2009

Primary Completion Date

August 31, 2015

Study Completion Date

August 31, 2015

Conditions
Peanut Hypersensitivity
Interventions
DRUG

Peanut Oral Immunotherapy

Peanut flour taken by mouth, given every day. Dose ranges from 0.2mg of peanut flour to 8000mg of peanut flour during the maintenance phase.

DRUG

Omalizumab

Omalizumab (anti-IgE) will be given for 4 months prior to starting oral immunotherapy. The medication is given as a subcutaneous injection with dose based on total IgE levels and weight at the beginning of the study. This medication is given for a total of 10 months.

Trial Locations (1)

27599

University of North Carolina, Chapel Hill

Sponsors

Collaborators (1)

Genentech, Inc.
All Listed Sponsors
collaborator

Genentech, Inc.

INDUSTRY

lead

University of North Carolina, Chapel Hill

OTHER